Chronic Inflammatory Demyelinating Polyneuropathy Market Size in the 7MM was ~USD 1.3 billion in 2023, estimated DelveInsight

DelveInsight's "Chronic Inflammatory Demyelinating Polyneuropathy Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding, historical and forecasted epidemiology, as well as the Chronic Inflammatory Demyelinating Polyneuropathy market trends in the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan.

The Chronic Inflammatory Demyelinating Polyneuropathy Market is an evolving segment of the global healthcare landscape, driven by the increasing Chronic Inflammatory Demyelinating Polyneuropathy prevalence of the disorder and the continuous development of innovative treatment options. The Chronic Inflammatory Demyelinating Polyneuropathy market encompasses various therapeutic categories, including antipsychotics, adjunctive therapies, and emerging treatment modalities.

Discover Key Insights into the Chronic Inflammatory Demyelinating Polyneuropathy Market with DelveInsight's In-Depth Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Size [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Key Takeaways from the Chronic Inflammatory Demyelinating Polyneuropathy Market Report

* In November 2024:- Octapharma- Multicenter, Prospective, Double-Blinded, Parallel Group, Randomized Phase III Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients
* As per DelveInsight's estimates, in the year 2023, the total prevalent cases of Chronic Inflammatory Demyelinating Polyneuropathy were 30,000 cases in the 7MM, which might rise by 2034 at a CAGR of XX%.
* EU4 and the UK, accounted for approximately 30% of the total prevalent cases of chronic inflammatory demyelinating polyneuropathy in the year 2023.
* In 2023, approximately 55% of chronic inflammatory demyelinating polyneuropathy (CIDP) cases in the United States occurred in males, driven by risk factors such as higher susceptibility to autoimmune diseases, specific HLA gene variations linked to CIDP, and greater exposure to occupational hazards that can trigger immune responses.
* The prevalence of inflammatory demyelinating polyneuropathy was notably higher among individuals over the age of 80 and above, reaching approximately 40% in 2023.
* Findings show that the prevalence of typical chronic inflammatory demyelinating polyneuropathy (CIDP) is slightly higher than that of the atypical form in the United States as of 2023.
* The leading Chronic Inflammatory Demyelinating Polyneuropathy Companies such as CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
* Promising Chronic Inflammatory Demyelinating Polyneuropathy Therapies such as Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.

Stay ahead in the Chronic Inflammatory Demyelinating Polyneuropathy Therapeutics Market with DelveInsight's Strategic Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Epidemiology Segmentation in the 7MM

* Total Prevalent Cases of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM [2020-2034].
* Gender-specific Cases of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM [2020-2034].
* Clinical Subtype based Diagnosed cases of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM [2020-2034].
* Age-Specific Prevalent Population of Chronic Inflammatory Demyelinating Polyneuropathy in the 7MM [2020-2034]

Download the report to understand which factors are driving Chronic Inflammatory Demyelinating Polyneuropathy epidemiology trends @ Chronic Inflammatory Demyelinating Polyneuropathy Prevalence [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Marketed Drugs

* Privigen: CSL Behring

Privigen (Immune Globulin Intravenous (Human), 10%) is the first and only, ready-to-use, sterile, room-temperature stored, liquid, polyvalent IVIG stabilized with L-proline. A naturally-occurring amino acid, proline has been shown to reduce IgG aggregation and dimer formation. The preparation is distributed with sub-classes of IgG and is extracted from large pools of human plasma by a combination of cold ethanol fractionation, octanoic acid fractionation, and anion exchange chromatography. The drug acts as an immunostimulant. It supplies a broad spectrum of opsonizing and neutralizing IgG antibodies against a wide variety of bacterial and viral agents.

* Hizentra: CSL Behring

Hizentra (Immune Globulin Subcutaneous (Human), 20%) is the first subcutaneously administered humanized immune globulin (SCIG) which is being developed by CSL Behring. The company has manufactured Hizentra from large pools of human plasma by a combination of cold alcohol fractionation, octanoic acid fractionation, and anion exchange chromatography. The Fc and Fab functions of the IgG molecule are retained. Fab functions tested include antigen-binding capacities, and Fc functions tested include complement activation and Fc-receptor-mediated leukocyte activation.

Chronic Inflammatory Demyelinating Polyneuropathy Emerging Drugs

* Riliprubart (SAR445088): Sanofi

Riliprubart is a potential first-in-class, IgG4 humanized monoclonal antibody that selectively inhibits activated C1s in the classical complement pathway of the innate immune system. By blocking C1s, riliprubart has the potential to inhibit key inflammatory mechanisms that drive demyelination and axonal damage in chronic inflammatory demyelinating polyneuropathy (CIDP). Riliprubart is currently under clinical investigation, and its safety and efficacy have not been evaluated by any regulatory authority. For more information on riliprubart clinical studies.

* Nipocalimab: Janssen Research & Development

Nipocalimab (also referred to as JNJ-80202135 or M281) is a fully human aglycosylated immunoglobulin IgG1 monoclonal antibody (mAb) designed to selectively bind, saturate, and block the IgG binding site on the endogenous neonatal Fc receptor. The drug is currently being evaluated for its efficacy and safety under Phase II/III clinical trials for treatment of chronic inflammatory demyelinating polyneuropathy.

Get In-Depth Knowledge on Chronic Inflammatory Demyelinating Polyneuropathy Market Trends and Forecasts with DelveInsight @ Chronic Inflammatory Demyelinating Polyneuropathy Treatment Market [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Chronic Inflammatory Demyelinating Polyneuropathy Market Outlook

The market size for chronic inflammatory demyelinating polyneuropathy in the seven major markets is projected to experience significant growth from 2024, driven by a notable increase in prevalent cases and the necessity for therapies that can provide more effective treatment to the affected patients. The total market size in the 7 major markets (7MM) was approximately USD 1.3 billion in 2023.

Scope of the Chronic Inflammatory Demyelinating Polyneuropathy Market

* Coverage- 7MM
* Chronic Inflammatory Demyelinating Polyneuropathy Companies- CSL Behring, Grifols, Kedrion Biopharma, Nihon Pharmaceutical, LFB, Teijin Pharma, OctaPharma, Shire, Takeda, UCB Biopharma, MedDay Pharmaceuticals, GeNeuro Pharmaceuticals, Pfizer, argenx, Momenta Pharmaceuticals, among others.
* Chronic Inflammatory Demyelinating Polyneuropathy Therapies- Riliprubart, Batoclimab 680 milligrams (mg) subcutaneous (SC) weekly, Efgartigimod PH20 SC, SAR445088 (IV), and others.
* Chronic Inflammatory Demyelinating Polyneuropathy Market Dynamics: Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers
* Chronic Inflammatory Demyelinating Polyneuropathy Market Access and Reimbursement, Unmet Needs and Future Perspectives

Unlock Strategic Insights with DelveInsight's Comprehensive Chronic Inflammatory Demyelinating Polyneuropathy Market Report @ Chronic Inflammatory Demyelinating Polyneuropathy Market Drivers and Barriers [https://www.delveinsight.com/sample-request/chronic-inflammatory-demyelinating-polyneuropathy-cidp-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]

Table of Content

1. Key Insights

2. Report Introduction

3. Chronic Inflammatory Demyelinating Polyneuropathy Market Overview at a Glance

4. Methodology

5. Executive Summary

6. Disease Background and Overview

7. Epidemiology and Patient Population

8. Treatment of Chronic Inflammatory Demyelinating Polyneuropathy

9. Diagnostic and Treatment Guidelines for Chronic Inflammatory Demyelinating Polyneuropathy

10. Unmet Needs

11. Patient Journey

12. Approved Therapies

13. Emerging Therapies

14. Market Analysis

15. KOL Views

16. Market Barriers

17. Market Drivers

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=chronic-inflammatory-demyelinating-polyneuropathy-market-size-in-the-7mm-was-usd-13-billion-in-2023-estimated-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/



This release was published on openPR.